NCT07272265 2025-12-09
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
Sun Yat-sen University
Phase NA Completed
Sun Yat-sen University
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal